TYME News and Press, Tyme Technologies Inc. From 08/10/21

– Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings – - Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used with methoxsale...

Company to report its first quarter fiscal 2022 financial results TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced...

G0d4ather/iStock via Getty Images Tyme Technologies ([[TYME]] -9.6%) surged over a quarter of value on Monday on the back of a patent win related to its metabolomic technology platform. However, today, the shares are on a downward trend for the second straight session since then to conti...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Tyme Technologies Inc. Receives Patent Notification for Metabolomic Technology Platform ” Tyme Technologies Inc (NASDAQ: TYME) surged over 54% in ...

Gainers: Tyme Technologies (TYME) +64%.Bit Digital (BTBT) +49%.SPAR Group (SGRP) +41%.Xenetic Biosciences (XBIO) +26%.IMV (IMV) +25%.Studio City International Holdings (MSC) +25%.Bitfarms (BITF) +24%.MicroStrategy (MSTR) +22%.Riot Blockchain (RIOT) +21%.RBC Bearings (ROLL) +19%.Losers: Iterum...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the focus for most of last week and today has been centered around cryptocurrency and public offerings, biotech companies have been quietly making a killing. New deals, patents, expansions and clinical trial results h...

IMV (IMV) +51%.Tyme Technologies (TYME) +35% granted U.S. patent claims covering use of Tyrosine-based drug delivery method to treat cancerDynatronics (DYNT) +33%.NanoVibronix (NAOV) +33%.Xenetic Biosciences (XBIO) +35% on $12.5M private placementBitfarms  (BITF) +19%.Bit ...

Tyme Technologies (TYME) shares surge more than 38% premarket after being granted additional patent claims related to the company’s metabolomic technology platform.The company received notification that the United States Patent and Trademark Office granting it the additional paten...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the...

At the conclusion of the 2021 Russell indexes annual reconstitution following notable healthcare stocks will join the Russell 3000 Index, effective June 28 after the U.S. market opens.Bionano Genomics (BNGO), Asensus Surgical (ASXC), Ocugen (OCGN), Senseonics Holdings (SEN...